Business
LiveWorld Reports First Quarter 2025 Financial Results
LiveWorld Reports First Quarter 2025 Financial Results.
About this update from Liveworld, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n LiveWorld Reports First Quarter 2025 Financial Results\r\n \r\n \r\n\r\n\r\nLiveWorld Reports First Quarter 2025 Financial Results\r\nLiveWorld looks to increase its AI investment\r\n\r\n\r\n\r\n\r\n\r\nCAMPBELL, Calif. and NEW YORK , May 08, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for first quarter 2025. Three Months 2025 Financial and Business Highlights \r\n Total three months revenues of $2.6 million\r\n Healthcare revenues of $2.3 million in Q1 2025\r\n Net loss from operations of $276,000 a reduction of 45% when compared to 2024\r\n Net Cash decreased by $1.6 million to $5.0 million from December 31, 2024\r\n Management Commentary “In the first quarter of the 2025 our total revenues were relatively flat when comparing 2024 to 2025, as both were approximately $2.6 million for the period, reflecting continued client concerns with the economy,” commented David Houston, Chief Financial Officer of LiveWorld. “For the rest of 2025 we will continue to invest in our AI initiatives, as well as look for growth opportunities from new and existing clients. These investments may lead to increment losses.” “For the three months ended March 31, 2025, we saw a cash burn of approximately $1.5 million for the period of net cash available for operations. This is a timing issue with contract renewals for 2025,” continued David Houston. “As we finalize these renewals, we see our accounts receivables grow, and in the first quarter our AR grew from approximately $682,000 to over $2.3 million, or almost $1.7 million. As we start to collect the receivables, we anticipate the cash will improve over the rest of 2025.” “Our focus continues to bring value to our clients through the integration of a human touch with advanced technology,” said Peter Friedman, LiveWorld Chairman & CEO. “To support this vision during 2024 and continuing in 2025 we are expanding our investment in AI. Our first dedicated AI product, the AI Pharma Brand Reputation Index, was launched in Q1. We expect to be in beta for our next generation of AI products later this year.” Financial Review for the Three Months Ended March 31, 2025 Total revenues were flat when comparing the first quarter of 2025 to 2024. Revenues were...